Baxalta US Inc.

UEI
LT5GEHL2F1K6
CAGE
7CZJ7
Primary NAICS
325412 Pharmaceutical Preparation Manufacturing
SAM.gov registration
Expired

Company facts

Self-certified in SAM.gov
  • Foreign Owned
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 -$11,867

Contract vehicles

Contract awards

Award Agency Obligated Awarded
Baxalta US INC.:1276806 [21-015888] glassia (alpha 1-proteinase inhibitor 75N90021P00727 NIH Clinical Center $12,054
Procurement of pharmaceutical needs. 75N90021P00606 NIH Clinical Center $10,332
Advate 1900 unit vials- QTY. 20 vials 36C25921F0372 Veterans Integrated Service Network 19 (VHA) $26,600
Ratification for gammagurd ordered 7/6/2020 36C26321N0774 Veterans Integrated Service Network 23 (VHA) $10,521
Advate 1900 unit vials 36C25921F0339 Veterans Integrated Service Network 19 (VHA) $13,300

Latest 5 listed here. See the rest on GovTribe.

Similar vendors

Vendor Location Primary NAICS
Grifols USA LLC UEI D48FNWJCJ5H5 Los Angeles, CA 325412 Pharmaceutical Preparation Manufacturing
TG Therapeutics Inc. UEI JKPZKD19WMD7 Morrisville, NC 325412 Pharmaceutical Preparation Manufacturing
Horizon Therapeutics Usa, Inc. UEI SK1UK7S74GB3 Deerfield, IL 325412 Pharmaceutical Preparation Manufacturing
Sanofi Genzyme UEI X2XMAQLR9DA8 Cambridge, MA 325412 Pharmaceutical Preparation Manufacturing
Takeda Pharmaceuticals America, Inc. UEI DDEVYUAXJ624 Cambridge, MA 325412 Pharmaceutical Preparation Manufacturing

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Baxalta US Inc. is a foreign owned, for-profit pharmaceutical company that provides drugs and biologics to government agencies through the GSA Pharmaceuticals and Drugs schedule contract. Baxalta specializes in treatments for bleeding disorders, immunodeficiencies, and other rare chronic conditions.

Through prime federal contract awards, Baxalta has provided specialty pharmaceuticals including ADVATE for hemophilia treatment, GAMMAGARD LIQUID immunoglobulin therapy, GLASSIA alpha 1-proteinase inhibitor, and FEIBA anti-inhibitor coagulant complex to the Department of Veterans Affairs, Department of Health and Human Services, Department of Justice Bureau of Prisons, and Defense Logistics Agency. The contract awards have been across multiple Veterans Integrated Service Networks and medical centers, the National Institutes of Health Clinical Center, Federal Correctional Institution Fort Worth, and Federal Medical Center Devens. The contract types have included purchase orders, delivery orders against Baxalta's GSA schedule contract, and IDIQ delivery orders valued up to $600,000. No set aside designations have been used.

Quick answers

Is Baxalta US Inc. registered in SAM.gov?

Baxalta US Inc.'s SAM.gov registration expired on December 10, 2021.

What is Baxalta US Inc.'s CAGE code?

Baxalta US Inc.'s CAGE code is 7CZJ7, and its Unique Entity ID (UEI) is LT5GEHL2F1K6.

Which contract vehicles does Baxalta US Inc. hold?

Baxalta US Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.

What is Baxalta US Inc.'s most recent federal award?

Baxalta US Inc.'s most recent federal contract award is Baxalta US INC.:1276806 [21-015888] glassia (alpha 1-proteinase inhibitor (75N90021P00727), from NIH Clinical Center, on September 17, 2021.

On GovTribe

See Baxalta US Inc.'s full federal record

  • Federal contract awards
  • IDV awards
  • Contract vehicles
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login

Find teaming partners on GovTribe